Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Fertin Pharma A/S has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 distinct examiners and 8 distinct art units, so the pending work is broadly distributed across examiners and nearly as broadly across art units.
PETRITSCH, AMANDA MICHELLE is the busiest examiner, with 1 pending matter. No examiner has more than that recorded assignment, which supports a decentralized prosecution approach. Counsel may benefit from tracking each matter independently while using consistent claim and disclosure positions across the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETRITSCH, AMANDA MICHELLE | 1 | 56.6% | +25.7% |
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
| PAK, JOHN D | 1 | 52.3% | +37.8% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
| YU, HONG | 1 | 31.1% | +5.7% |
| JACOBSON, MICHELE LYNN | 1 | 28.1% | +33.9% |
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 30d |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612007 | Carrier Systems For Cannabinoids | YOUNG, MICAH PAUL | 12d |
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 30d |
| 19046728 | Oral Powder Mixture With Small Sized Particles | PETRITSCH, AMANDA MICHELLE | — |
| 18876619 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | VIGIL, TORIANA NICHOLE | — |
| 18958419 | Soft Chew Tablets Suitable For Antacids | PAK, JOHN D | — |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| 1699 | 1 |
| 1616 | 1 |
| 1618 | 1 |
| 1614 | 1 |
| 1793 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19046728 | Oral Powder Mixture With Small Sized Particles | PETRITSCH, AMANDA MICHELLE | 1612 | §103§112DP | Non-Final OA | — | Pending | Feb 06, 2025 |
| 18876619 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | VIGIL, TORIANA NICHOLE | 1612 | §103DP | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18958419 | Soft Chew Tablets Suitable For Antacids | PAK, JOHN D | 1699 | §103Other | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18612007 | Carrier Systems For Cannabinoids | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 12d | Pending | Mar 21, 2024 |
| 18612256 | Cannabinoid Self-Emulsifying Systems | YU, HONG | 1614 | §103DP | Final Rejection | — | Pending | Mar 21, 2024 |
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 1793 | §103 | Final Rejection | 30d | Pending | Jul 05, 2022 |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | 1613 | §103§112 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFertin Pharma A/S has 8 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Amanda Michelle Petritsch has the most, with 1 of Fertin Pharma A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
